Preclinical data show that the combination of gilteritinib with VEN synergistically enhances apoptosis and reduces viability in both AZA/VEN-resistant cell lines and primary patient samples, even in wild-type FLT3 AML, by decreasing MCL1 levels [74]. The gene discussed is MCL1; the disease is acute myeloid leukemia.